We are live on ! Find out more
46.52 USD
+0.46
1%
At close Updated Nov 20, 4:00 PM EST
Pre-market
After hours
46.52
0.00
0%
1 day
1%
5 days
-4.71%
1 month
12.37%
3 months
3.03%
6 months
4.14%
Year to date
-3.55%
1 year
-4.85%
5 years
-6.9%
10 years
15.84%
 

About: Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Employees: 74,846

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 63.9%
Neutral 31.1%
Negative 4.9%
Neutral
Benzinga
1 day ago
Potential Sanofi-Insmed Deal: Analysts Split on Financial Strain Versus Pipeline Gains
French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is reportedly exploring a potential acquisition of  Insmed Inc. (NASDAQ:INSM).
Potential Sanofi-Insmed Deal: Analysts Split on Financial Strain Versus Pipeline Gains
Neutral
MarketBeat
2 days ago
Sanofi Maps Vaccine Pipeline With Flu-COVID and Pneumococcal Trial Results Ahead
Sanofi NASDAQ: SNY is advancing a slate of vaccine candidates targeting respiratory infections, pneumococcal disease and acne, with several clinical readouts expected over the next 18 months, according to its head of vaccines research and development.
Sanofi Maps Vaccine Pipeline With Flu-COVID and Pneumococcal Trial Results Ahead
Positive
Proactive Investors
2 days ago
Insmed shares jump 18% as Sanofi weighs potential takeover
Insmed Incorporated (NASDAQ:INSM) shares surged on Thursday after reports that French pharmaceutical group Sanofi is considering an acquisition of the US biotechnology company, which has a market value of about $26.28 billion. On Thursday afternoon, Insmed was trading at $141.84, up $22.04, or 18.4%.
Insmed shares jump 18% as Sanofi weighs potential takeover
Negative
CNBC
2 days ago
As Sanofi's Pompe drug shortage drags on, some patients struggle to access treatments
A shortage of Sanofi's Pompe disease drugs has lasted for more than three months, forcing some patients to miss critical infusions. Sanofi says the shortage is due to manufacturing issues at its facility in Ireland.
As Sanofi's Pompe drug shortage drags on, some patients struggle to access treatments
Positive
Investors Business Daily
2 days ago
Sanofi Reportedly Gears Up For The Biggest Biotech Deal In Years
Insmed stock surged Thursday on a rumored bid from French pharma giant Sanofi. The deal would be one of the largest in recent history.
Sanofi Reportedly Gears Up For The Biggest Biotech Deal In Years
Positive
24/7 Wall Street
2 days ago
3 Big Pharma Dividend Stocks Built for Retirement Income
Three drugmakers promise retirees steady paychecks, yet one faces a looming Eliquis cliff and two pay in foreign currencies that can shrink the check. Which dividend is safest when earnings look shaky but cash tells a different story?
3 Big Pharma Dividend Stocks Built for Retirement Income
Positive
Zacks Investment Research
2 days ago
Sanofi's Next-Generation Rabies Vaccine Secures Approval in EU
SNY wins EU approval for VaxRabeo, its next-generation rabies vaccine, offering improved stability, flexible dosing and reduced allergy risks.
Sanofi's Next-Generation Rabies Vaccine Secures Approval in EU
Positive
Zacks Investment Research
2 days ago
SNY Wins FDA Approval for Infilbray in Type 3 Gaucher Disease
Sanofi gains FDA approval for Infilbray, the first U.S. therapy targeting progressive neurological symptoms of type 3 Gaucher disease.
SNY Wins FDA Approval for Infilbray in Type 3 Gaucher Disease
Positive
Barrons
2 days ago
Insmed Stock Already Was Flying High. Sanofi Takeover Buzz Lights the Afterburners.
Insmed stock jumps following a report saying Sanofi is eyeing a takeover of the biopharma company.
Insmed Stock Already Was Flying High. Sanofi Takeover Buzz Lights the Afterburners.
Positive
Benzinga
3 days ago
Dual Regulatory Wins for Sanofi Bring New Oral Gaucher Therapy and Upgraded Rabies Shot
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Sanofi SA's (NASDAQ:SNY) Infilbray (venglustat), a novel, oral glucosylceramide synthase inhibitor (GCSi) that acts across the blood-brain barrier, for neurological manifestations of Type 3 Gaucher disease (GD3) in adults and pediatric patients.
Dual Regulatory Wins for Sanofi Bring New Oral Gaucher Therapy and Upgraded Rabies Shot
Price charts implemented using Lightweight Charts™